A Janus-headed electrolyte and ‘RALES’ disease

Daniel Kraus, Christoph Wanner and Bettina J. Kraus

Divisions of Nephrology and Cardiology, 1st Department of Medicine, Comprehensive Heart Failure Centre (CHFC), Würzburg University Hospital, Würzburg, Germany

In ancient Roman mythology, Janus is the god of beginnings and transitions. Janus has two faces, one looking back into the past and one looking ahead into the future (Figure 1). According to Ovid, having two faces also enabled him to never turn his back on his adored Cardea.1 In the figurative sense, something that is Janus-headed is ambivalent and must be seen in context. In this regard, potassium is the Janus among electrolytes in heart failure.

Potassium is abundant in cells and sparse in the extracellular space. This concentration gradient helps to build up the transmembrane potential that is indispensable for electrical signal conduction in the heart and in other organs. A decrease in extracellular potassium concentration augments, and an increase dampens excitability. Both conditions can severely impair normal physiological function. Serum potassium levels are largely determined by urinary potassium excretion.2 By acting on the expression of sodium and potassium transporters in the collecting tubules, the renin–angiotensin–aldosterone system (RAAS) causes sodium retention and potassium excretion.

In patients with heart failure (HF), low levels of serum potassium are associated with increased mortality. Potassium depletion may result from neurohumoral RAAS activation in these patients, as well as from diuretic treatment, a mainstay in the management of heart failure. In the SOLVD trial cohort, the use of non-potassium-sparing diuretics was an independent risk factor for sudden cardiac death.3 The RALES, EPHESUS, and EMPHASIS-HF trials have firmly established the role of potassium-sparing mineralocorticoid receptor antagonists (MRA) in the treatment of heart failure.4–6 Aldosterone and eplerenone retain potassium and have direct effects on the myocardium. Because aldosterone levels are often increased despite RAAS blockade,7 simultaneous application of MRA has an additive effect over ACE inhibitors and angiotensin receptor blockers.

On the other hand, the concomitant use of MRA and other RAAS blocking agents may put patients at risk of fatal arrhythmias due to hyperkalaemia—Janus’ second face. This is most commonly seen in those that exhibit reduced aldosterone levels in the first place, e.g. due to hyporeninaemic hypoaldosteronism.8 Elderly patients and those with diabetes mellitus or/and kidney disease are at highest risk.

In the wake of the landmark MRA trials, the prescription rates for MRA have sharply increased.9,10 A concomitant increase in the rates of hyperkalaemia has been reported in one study (Figure 2),9 but not in another.10 However, the coincidence of hospital admissions due to very severe hyperkalaemia and the dual use of MRA and other RAAS blocking medications is now such a commonplace clinical experience that the term ‘RALES’ disease’ (Morus RALES) has gained currency among emergency physicians.

To assess the actual risk of patients on dual MRA and other RAAS blocking treatment, we queried Würzburg University Hospital’s Clinical Data Warehouse (Table 1). The Data Warehouse is a clinical registry that includes every inpatient and outpatient case managed by any department at this tertiary care centre. Out of ~5 million cases, we identified 118 691 cases (2.4%) between 2003 and January 2017 with at least one RAAS blocking agent (including an MRA). Dual

Figure 1 Coin depicting Janus. This image is in the public domain. Source: https://commons.wikimedia.org/w/index.php?curid=34884498
prescription of an MRA and another RAAS blocking agent increases the risk of ‘RALES’ disease across all strata of renal function (Table 1).

It is important to realize that a patient’s individual risk of developing ‘RALES’ disease may change over time. It literally changes over time as a patient gets older, because renin and aldosterone levels decline in senescence. Diabetics may gradually develop nephropathy and hyporeninaemic hypoaldosteronism. Acute kidney injury or acute renal failure may occur in any patient. Thus, it is not only important to frequently monitor patients that receive standard of-care treatment for heart failure; it is also paramount to be aware of acute changes in a patient’s condition that may precipitate ‘RALES’ disease.

To prevent hyperkalaemia, patients with chronic kidney disease or diabetes mellitus should be counselled to reduce dietary potassium intake (for patients with mildly impaired renal function, there is evidence that potassium supplementation may slow the progression of kidney disease). However, in many cases, dietary restriction will not be sufficient.11 Fortunately, there are pharmacological remedies. One approach is to co-administer potassium binding agents. Sodium polystyrene sulphonate, an ion exchange resin, has been widely used for over 50 years, but its efficacy and safety have been questioned.11,12 Patiromer and sodium circonium cyclosilicate (ZS-9) are two alternative ion exchange agents. Patiromer effectively prevents ‘RALES’ disease with normal and reduced renal function.11 It binds molecules other than potassium as well and may affect the bioavailability of drugs. Because of this, the United States Food and Drug Administration (FDA) requires a boxed warning, and patients should not take patiromer within 3 hours before or after other medication. This may have implications for patients’ adherence to therapy. Patiromer has been approved by the FDA, but not yet by the European Medicines Agency (EMA).

Similar to patiromer, ZS-9 also effectively lowers potassium levels.11 ZS-9 has been denied approval by the FDA due to manufacturing issues,13 but has received a favourable opinion by the EMA’s Committee for Medicinal Products for Human Use in February 2017.

Because patiromer and ZS-9 are novel drugs, there is no experience with long-term administration of either of them. Patiromer has been studied for up to 12 months and ZS-9 for...
up to 4 weeks. Long-term safety data on frequency and clinical relevance of drug interactions and adverse effects are needed.

Finerenone is a novel, non-steroidal MRA. Compared with spironolactone and eplerenone, it has higher relative affinity for the heart than for the kidney. In theory, this should allow for better efficacy and lower risk of hyperkalaemia. However, in the recently published ARTS-II study, the rates of hyperkalaemia were comparable between the finerenone and eplerenone treatment groups.14

Regardless of the approach taken to lower potassium levels, patients at risk for life-threatening hyperkalaemia must be monitored frequently, especially elderly patients and those with diabetes mellitus and chronic kidney disease. The European Society for Cardiology and the American Heart Association both offer detailed practical guidance.15,16 Importantly, acute events such as infection, dehydation, or newly prescribed medications that affect renal blood flow and glomerular perfusion (e.g., non-steroidal anti-inflammatory drugs) may precipitate ‘RALES’ disease’. Therefore, it is imperative to be alert for such changes in patients at risk.

Taken together, ‘RALES’ disease’ is more than a snappy term from the emergency room. It is an admonisher that benefit and risk are the two faces of the same coin, and just like Janus in his courting Cardea, we should never turn our back on our most vulnerable patients.

Acknowledgement

The authors are indebted to Georg Fette, MSc, of the Department for Artificial Intelligence and Applied Computer Science of the University of Würzburg for performing the Data Warehouse query.

Conflict of interest

None declared.

References

1. Ovid BAJ, Woodard RD. Liber VI. Fasti. London: Penguin Books; 2004.
2. Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol 2009; 71: 381–401.
3. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311–1315.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.
5. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHEMIS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643–1650.
6. Zannad F, McMurray J, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Epereone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.
7. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002; 106: 1055–1057.
8. Palmer BF. Managing hyperkalaemia caused by inhibitors of the renin-angiotensin-aldoesterone system. N Engl J Med 2004; 351: 585–592.
9. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalaemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–551.
10. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010; 340: c1769.
11. Cowan ACJ, Gharib EG, Weir MA. Advances in the management of hyperkalaemia in chronic kidney disease. Curr Opin Nephrol Hypertens 2017; 26: 235–239.
12. Sterns RH, Grief M, Bernstein PL. Treatment of hyperkalaemia: something old, something new. Kidney Int 2016; 89: 546–554.
13. Reuters. AstraZeneca receives FDA setback for high potassium drug. The New York Times 2017.
14. Filippatos G, Anker SD, Böhm M, Gheorghiea M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim S-Y, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016; 37: 2105–2114.
15. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Piecke B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.
16. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: e240–e327.

DOI: 10.1002/ehf2.12173